Branstetter J, Searcy H, Benner K, et al. - This retrospective chart review was performed at a cystic fibrosis (CF) center to ascertain ceftaroline efficacy vs vancomycin in the treatment of methicillin‐resistant Staphylococcus aureus (MRSA) associated acute pulmonary exacerbations (APEs). This analysis involved patients 0 to 21 years of age with CF admitted for an APE and managed with either vancomycin or ceftaroline between January 2016 and August 2018. In terms of observed improvement in lung function from admission to discharge, ceftaroline was not different than vancomycin. Also, mean forced expiratory volume in 1 second or readmission rate did not differ between the two groups. In pediatric CF patients with APEs, ceftaroline may afford an effective as well as safe intravenous antimicrobial choice for targeting MRSA.